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Although the transmission of blood-borne viral infections such as HIV and hepatitis C virus among people who inject drugs has garnered substantial attention, there has been less focus on other injecting-related injuries and diseases (IRID) in this population. These commonly include soft tissue infections such as abscesses and cellulitis, which occur as a result of micro-organisms (i.e. bacteria and fungi) in the injecting environment. Other infections may include bone and joint infections, infective endocarditis, and sepsis; these can arise as a result of direct introduction of bacteria to the bloodstream, or as complications of untreated of soft tissue infections. 1 In addition to infections, repeated injecting and poor injecting technique may lead to vascular injury and poor venous access; furthermore, drug solutions may contain inactive ingredients that are not water soluble, leading to particles in the vasculature that can cause inflammation and formations of clots. 2, 3 The likelihood of vascular injury can be further exacerbated by the delivery method (e.g., intravenous versus intramuscular injection), injecting site (e.g., subcutaneous tissue and muscle, major vessels), and type of equipment used. 4 Some IRID necessitate urgent medical care, and all can result in poorer health outcomes for people who inject drugs, including risk of mortality, if untreated. 5 From an economic perspective, the costs of hospital care for IRID can be substantial. 6, 7 A clearer understanding of the prevalence of IRID is needed to determine the scale of the problem and guide the development of evidence-informed responses. This review aimed to assess prevalence of non-viral IRID among people who inject drugs.
Method
This review is reported in line with the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) checklist. 8 
Search strategy and study selection
We searched MEDLINE, Embase and CINAHL for relevant literature using search strings developed in consultation with a specialist drug and alcohol librarian (see supplementary materials). Searches were undertaken in February 2014 and updated in July 2015. Search results were catalogued using Endnote X6. Titles and abstracts were independently screened by SL and a research assistant to produce a shortlist of potentially relevant reports. The full text of each shortlisted report was retrieved and read to determine eligibility for inclusion in the review. For articles in languages other than English, eligibility for the review was determined based on information available in English translations of abstracts.
Reports were eligible for inclusion in the study if they included data on the prevalence of, or risk factors for, any non-viral IRID in a sample of people who injected illicit drugs. Reports could include data on any IRID, but data were required to be specific to a named infection, injury or disease, rather than a combination of different types of IRID. Where there was clearly overlap between reports in terms of the study sample (e.g. multiple reports from one study, sometimes using sub-samples of a larger sample) and types of IRID reported, we included only the study with the largest sample size. If multiple reports from the same study reported the same IRID over different prevalence periods, all reports were included.
Articles that reported on specific sub-groups of people who inject drugs, such as HIV-infected injectors, or groin injectors, were excluded. Reports based on samples of people who exclusively injected performance and image-enhancing drugs were excluded, as this group is distinct from people who inject illicit drugs in terms of frequency of injecting, intravenous versus intramuscular injecting, and the environmental and social contexts of injecting. Reports that included data on pathology within people who inject drugs, that was not directly linked to injecting, were excluded.
Data extraction
Data were independently extracted by SL and a research assistant, with discrepancies resolved through discussion and consultation with BM. Data extracted from each article included sampling approach; demographic characteristics of the sample; types of IRID assessed; whether IRID ascertainment was based on self-report, clinical examination, or medical records; denominator and numerator for each IRID reported; and measures of association between IRID and other factors.
Risk of bias assessment
There is no 'gold standard' for the assessment of risk of bias in systematic reviews of epidemiological or observational studies. We considered two existing tools, one designed for use with populationbased epidemiological surveys, 9 and the other for assessing HIV prevalence and risk in convenience samples of men who have sex with men. 10 These were adapted to produce a five-item risk of bias tool. This assessed sampling approach; response rate; whether data were based on self-report or clinical examination/medical records; in the case of self-reported data, whether steps were taken to increase the validity of self-reports (e.g. providing participants with a definition of the IRID in question; symptom checklists); and completeness of reporting (i.e. all numerators and denominators reported). The findings of the risk of bias assessment informed interpretation of the quantitative data and meta-analyses.
Data synthesis and analysis
The various IRID that were identified through the literature search were categorised post hoc into the following categories: skin infections at injection sites (e.g. abscess, cellulitis); infective endocarditis; sepsis/septicaemia; bone and joint infections (e.g. osteomyelitis, septic arthritis); other infections; thrombosis and emboli; and other pathology and dysfunction associated with injecting drug use. Given wide variation between studies in reported prevalence estimates, data were not synthesised. Results for each study are presented graphically, by prevalence period.
We had planned to do stratified meta-analyses by sex, age, duration of injecting, injection frequency, primary drug injected, and engagement in harm reduction strategies (i.e., opioid substitution treatment (OST); needle and syringe programs (NSPs); and supervised injecting facilities) in order to identify potential risk and protective factors for IRID. However, many studies did not report the necessary data (i.e. insufficient information on group numerators and denominators), or only that there was a lack of a statistically significant association between the variable and outcome (without an odds ratio or numerators/denominators). Consequently a narrative review is presented for each IRID where data were available in reference to the selected risk/protective factors.
Results
The literature searches returned 3,578 unique records. Of these, 3,254 were deleted following screening of titles and abstracts, leaving 324 reports to be reviewed in full. Thirty-two reports met the inclusion criteria; 29 reports provided data on IRID prevalence, and 16 provided data on IRID risk factors ( Figure 1 ). Included studies were largely from high-income countries, and participants were typically recruited from needle and syringe programs and drug treatment clinics. The IRID most frequently included in reports was skin infections (Table 1 ).
*** Figure 1 approximately here*** *** Table 1 approximately here***
Skin infections at injecting sites
Twenty-two reports presented data on the prevalence of skin infections at injecting sites ( Figure 2 and Supplementary Table 2 ). Terminology for skin infections varied across reports. The majority referred specifically to abscesses, but some used terms such as "injection site infection".
Seven reports provided estimates of current/past month abscess prevalence, which ranged between 6.1% (95% CI: 4.6%, 7.9%) and 32.0% (25.0-39.6%); four of these included a physical examination to confirm the presence of infection (prevalence estimates in these studies ranged from 10.0-32.0%).
Eleven reports provided estimates of 6-12 month prevalence, which ranged between 6.9% (4.6-9.8%) and 37.3% (34.1-40.6%); and 12 reports estimates of lifetime prevalence, which ranged between 6.2% (5.8-6.7%) and 68.6% (56.4-79.1%) ( Figure 2 ). *** Figure 2 approximately here*** Women generally had greater odds than men of skin infections at injecting sites, with six studies finding this association, although three additional studies showed no statistically significant association (two following adjustment for confounders) ( Table 2) . Seven of eleven studies showed no significant association between age and current/past 6-12 month skin infection; the remaining studies reported greater odds of skin infection with older age (typically ≥30 years). Of seven studies examining duration of injecting, two had insufficient evidence of an association with skin infections;
four reported greater risk of skin infection with increasing duration of injecting; and one reported only p<.001, without indicating the direction of the association. The literature was divided in regards to frequency of injection as a risk factor for skin infection ( of past 12-month skin infections at injecting sites (data not shown).
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While there was no significant association between always injecting in a supervised injecting facility and skin infection after adjustment for confounders (one study), contradictory findings were evident for NSP and OST involvement. Specifically, two studies found no significant association between NSP use and skin infection; one study showed increased odds of skin infection with past 12-month use of NSP services; and one study reported lower odds of skin infection with a greater number of needles exchanged at a NSP. For OST, one study showed greater odds of past 12-month skin infection with lifetime OST involvement relative to no involvement; another found greater odds of past 12-month skin infection with previous OST involvement (but not no OST involvement) relative to current involvement; and another showed no significant association. *** Table 2 approximately here***
Infective endocarditis
There were eight reports assessing prevalence of infective endocarditis (Supplementary Table 3 ; Figure 3 ). All studies relied on self-reported data. 12 6-12 month prevalence was 1.3% (two studies) and lifetime prevalence ranged between 0.5% (0.06-1.8%) and 11.8% (4.4-23.9%). One study found increased risk of infective endocarditis with older age and longer injecting career; no significant association was observed with participant sex. 12 *** Figure 3 approximately here***
Sepsis/septicaemia
Six reports contributed data on the prevalence of sepsis or septicaemia (Supplementary Table 4 ).
Reported 6-12 month prevalence was 1.0% (0.1-3.6%) and 1.3% (0.4-2.9%) in two studies. Lifetime prevalence varied between 2.0% (951.7-2.3%) in an Australian sample and 9.8% (3.3-21.4%) in a US sample ( Figure 4) . No studies were identified reporting on the association between the chosen risk factors and prevalence of sepsis/septicaemia. *** Figure 4 approximately here***
Bone and joint infections
Two reports were identified that provided data on bone and joint infections; specifically, septic arthritis and osteomyelitis (Supplementary Table 5 ). Self-reported lifetime prevalence of septic arthritis was 1.0% (0.3-2.6%) in an Australian convenience sample 5 , and 2.0% (0.05-10.4%) in a US convenience sample 13 . In the same reports, lifetime prevalence of osteomyelitis was 0.5% (0.006-1.8%) 5 and 0%
13
. No studies were identified reporting on the association between the chosen risk factors and prevalence of bone and joint infection.
Other infections
Three reports provided data on other infections (Supplementary . No studies were identified reporting on the association between the chosen risk factors and prevalence of other infections.
Thrombosis and emboli
Nine reports provided data on thrombosis and emboli, including venous thromboembolism, thrombophlebitis and deep vein thrombosis. Three studies reported 6-12 month prevalence of thrombosis, which ranged between 1.3% (0.4-2.9%) and 9.0% (5.4-13.9%; Figure 5 ). Lifetime prevalence based on six studies (five of which were conducted with Australian convenience samples)
varied between 3% (2%-6%) and 27% (14-44%). No studies were identified reporting on the association between the chosen risk factors and prevalence of thrombosis and emboli. *** Figure 5 approximately here***
Other and non-specific pathology and dysfunction
Three reports explored other pathology and dysfunction associated with injecting drug use. Table 8 ). A longer history of injecting was strongly associated with more severe chronic venous insufficiency. 15 Other identified pathology included venous ulcer; hand oedema ('puffy hand syndrome'), and injecting sinus (Supplementary Table 8 ).
Risk of bias assessment
The complete risk of bias assessment is provided in Supplementary Table 1 . The majority of included reports (24/32; 75%) used non-probability sampling methods such as convenience sampling.
Response rates were rarely reported, but were above 65% in those studies that noted the response rate. IRID were confirmed through clinical assessment or medical record review in 6 reports, with the remaining 26 reports relying solely on self-reported history of IRID. Of the latter, nearly half (n=12) noted steps that were taken to enhance the validity of self-reports, such as asking participants to describe signs and symptoms, or providing participants with clear definitions of specific IRID.
Discussion
This review has shown that IRID are a common consequence of injecting drug use. Existing studies have found that between 6-32% of people who inject drugs may have experienced injections at injecting sites within the previous month. Serious complications of injecting are also a risk, with studies finding that 0.5-11.8% may have experienced infective endocarditis and 2-9.8%, septicaemia, at some point in their lives.
Although risk factors for skin infections were not able to be formally meta-analysed, IRID appear more common among women than men, and with increasing duration of injecting drug use.
Conflicting evidence was identified with regards to the impact of harm reduction interventions such as needle and syringe programs and opioid substitution therapy on injecting-related injuries and diseases; there is a need for research focusing upon the potential impact of injecting risk reduction interventions on these consequences of injecting.
Studies were largely from high-income countries, with participants typically in contact with services for people who inject drugs, such as needle and syringe programs and drug treatment clinics. These factors should be borne in mind when considering the generalisability of findings to other settings.
The majority of studies relied on self-reported data on injecting-related injuries and diseases, although 12 studies did incorporate measures designed to improve the reliability of self-reports.
Estimates from studies using those strategies were similar to those relying solely on self-report.
There was variation between studies in how specific injecting-related injuries and diseases were defined. These inconsistencies contribute to difficulties in synthesising data. Other studies reported only 'composite' variables that combined mild, non-specific problems (e.g. soreness at injecting sites) with more severe concerns such as infective endocarditis, obscuring the extent of more serious injecting-related injuries and diseases.
Given the wide variation in prevalence estimates between studies, it was not possible to develop summary estimates of specific injecting-related injuries and diseases. Further, we were unable to formally synthesise data on risk factors for injecting-related injuries and diseases due to a lack of data suitable for meta-analysis.
Implications
There is an obvious opportunity for research examining correlates and potential risk and protective factors for the range of injecting-related injuries and diseases. These studies should adopt a consistent list and operationalised definition of specific injecting-related injuries and diseases. An alternative to cross-sectional surveys would be to identify population cohorts of people who inject drugs via administrative data (e.g. drug treatment registrations) and link these to hospitalisation and mortality data. This would allow for generation of incidence and mortality rates and comparisons to the general population.
There is a very high likelihood that not all people who inject drugs will have the same level of risk for injecting-related injuries and diseases. Differential risk may arise as a result of the types of drugs injected; in the United States, cities dominated by black tar heroin have twice the rate of hospitalisations for opiate-related skin and soft tissue infections compared to cities where powder heroin predominates. 17 People who inject pharmaceuticals may be more likely to experience vascular harms given insoluble particles in drug solutions. 3 Intensive periods of frequent injecting, often associated with methamphetamine and cocaine use, may also impact on risk. These questions all require further exploration to assist in targeting prevention activities for injecting-related injuries and diseases.
The data presented here were not able to clearly identify risk or protective effects of harm reduction interventions on injecting-related injuries and diseases. Positive associations between needle and syringe program attendance or opioid substitution therapy and skin infections at injecting sites may reflect higher risk injectors making use of these services, or help-seeking following an infection.
Population-level impacts of needle and syringe programs on injecting-related injuries and diseases have been reported elsewhere. In one study, for every eight visits to a needle and syringe program, one fewer abscess was treated at community health centres. 18 Harm reduction services may also offer opportunities to provide treatment for injecting-related injuries and diseases. 19 There is a clear need to assess the impact of needle and syringe programs and opioid substitution therapy on injecting-related injuries and diseases, including cost-benefit analyses.
Conclusion
IRID appear to be highly common among people who inject drugs, but there is suggestive evidence that prevalence varies widely according to context. There is a need for robust, reliable data on the range of injecting-related injuries and diseases among people who inject drugs, particularly in lowand middle-income countries. Studies should adopt consistent definitions of injecting-related injuries and diseases and ensure transparent reporting of prevalence estimates and risk analyses. 
